derivatives has been optimized by modifying the C-3 ester promoiety. Pivaloyloxymethyl (li?,5S,6S)-
6-[(JR)-l -hydroxyethyl]-l -methyl-2-[(jR)-5-oxopyrrolidin-3-ylthio]
-l -carbapen-2-em-3-carboxylate, CS-834, has been selected as the most promising compound for further evaluation.
An orally active antibiotic with potent activity is of much interest in the clinical realm because oral administration and lower dosage are advantageous for patients.
Carbapenems are the most potent jS-lactam antibiotics which have a broad antibacterial spectrum and potent The chemical instability of carbapenem has been recognized as a serious problem for the development of oral carbapenem, although Ij6-methyl substitution of carbapenem improved its stability to some extent.12) We expected that ljS-methylcarbapenems could be stable enough for oral administration by preferable contribution of the ljS-methyl group, and that the dosage could be reduced as a result of their powerful antibacterial effects.
Wehave synthesized a variety of l/?-methylcarbapenems derivatized at the C-2 side chain and evaluated them for antibacterial activities and other biological properties. Wehave found that some derivatives having an amide group in the C-2 side chain show potent and 429 well balanced antibacterial activity as well as high stability against dehydropeptidase-I. These compounds have been submitted for prodrug approach to optimize oral absorption. Through the investigation we have successfully obtained an orally active carbapenem, pivaloyloxymethyl (ljR,55' ,65r)-6-[(^)-l-hydroxyethyl]-l -methyl-2-[(7?)-5-oxopyrrolidin-3-ylthio]-l -carbapen-2-em-3-carboxylate (CS-834). 1 3) In this paper we will describe the synthesis and structure-activity relationship of CS-834 and related compounds.
Chemistry
The C-2 substituted derivatives of carbapenems were synthesized through the general procedure shown in Scheme1. It includes condensation of the carbapenem-2-yl diphenylphosphate 112'14> with appropriate thiol 3a~n designed for the C-2 side chain to give carbapenem ester 4a~n, and the following deprotection of the 4-nitrobenzyl group by catalytic hydrogenation using 10%palladium on charcoal. The resulting carbapenem derivatives 6a~n were purified by reversed phase column chromatography and lyophilized as sodium salts. The 1-H carbapenem 7m, which has the same C-2 side chain as the derivative 6m, was also prepared in a similar way.15>16) Synthesis ofderivatives 6a~61 will be reported elsewhere. The sodium salt 6m (R-83201) was converted to the corresponding free acid (R-95867) by treatment with 1n HC1in water.
Optically active (R)-and (S)-4-mercapto-2-oxopyrrolidine 3m and 3n were prepared starting from (£)-and (jR)-4-hydroxy-2-oxopyrrolidine 8,x7) respectively, as The antimicrobial activity (MICs) of carbapenems are shown in Tables 1 and 2.   431 First of all, the antimicrobial activity of aromatic and heteroaromatic derivatives which have a carboxamide group in the C-2 side chain were examined. The carbapenem 6a, which has only a phenylthio group, showed excellent activity against Gram-positive bacteria such as Staphylococcus aureus, but it was inactive against a MICwas determined by agar dilution method with an inoculum of 107 cfu/ml. b Urinary recovery (%) was determined by disk method using Bacillus subtilis ATCC6633 as a test strain after subcutaneous administration of compound (50mg/kg) in SPF ddY mice (n=5, 0~24 hours). a MICwas determined by agar dilution method with an inoculum of 107 cfu/ml. b Urinary recovery (%) was determined by disk method using Bacillus subtilis ATCC6633 as a test strain after subcutaneous administration of compound (50mg/kg) in SPF ddY mice (n=5, 0~24 hours). c GV104326was synthesised according to Glaxo's patent procedure.
both Gram-positive and -negative bacteria. As for the configuration at the C-3 position of 5-oxopyrrolidine, the (i^)-isomer 6m was slightly more active than the (S)-isomer 6n against S. aureus, E. faecalis and some
Gram-negative bacteria.
The 1-H carbapenem 7m which has the same C-2 side chain as compound6m showed similar activity to 6m. The antimicrobial activity of 6m is superior to that of cefpodoxime (CPDX)20) and almost equal to that of parenteral carbapenems such as imipenem and panipenem. However, they are less active against Pseudomonas aeruginosa. A new tricyclic /Mactam, GV-104326, seems to be inferior to compound 6m in antibacterial activity against Gram-negative bacteria. The urinary recovery of carbapenemswas determined after subcutaneous administration to mice in order to estimate stability of carbapenems under biological conditions. Derivatives having an alkyl or cyclic amide were recovered in moderate amounts (40~75%) as shown in Tables 1 and 2 . Somestereoselective effects of the chiral center in the C-2 side chain were observed in urinary recovery. As to the alkyl amides 6i and 6j, recovery of the (i^-isomer 6j was less than that of the (S)-isomer 6i although 6j had better antibacterial activity. With respect to the cyclic amides 6m and 6n, urinary recovery was highly dependent on the configuration at the C-3 position of 5-oxopyrrolidine. The recovery of the (TQ-isomer 6m was 75%, although the recovery of the (S)-isomer 6n was only 46%. Carbapenems (50 mg/kg) were subcutaneously administered to mice (n=5) with or without cilastatin (CS:
50mg/kg as sodium salt). Urinary recovery was determined by the same method described in Table 1 . Mouse renal dehydropeptidase-I (DHP-I) was used. The figures are relative to the degradation rate of 6m.
Simultaneous administration of cilastatin, an inhibitor of dehydropeptidase-I, with the (S)-isomer 6n resulted in improved urinary recovery equal to that of the (R)-isomer 6m. In addition, the degradation rate of 6m
with mouse dehydropeptidase-I (DHP-I) was slower than that of 6n as listed in Table 3 . These results clearly demonstrate that the (iQ-isomer 6m is reliable in the biological system due to higher resistance against DHP-I in mice.2X)
The recovery of the 1-H carbapenem 7m was only 8%, which was in accordance with the fast degradation by DHP-I as listed in Table 3 . The urinary recovery of 7m was increased to 64%by coadministration with cilastatin. This result shows that the 1-H carbapenem 7m is very labile in mice due to degradation by DHP-I. From these experiments the ljS-methylcarbapenem 6m which has an (if)-5-oxopyrrolidin-3-ylthio substitution at the C-2 position has been selected as the best parent compoundfor the following prodrug approach.
In order to optimize the oral absorption of the carbapenem6m, several ester derivatives were prepared as described above. The oral absorption of a prodrug can be estimated from its urinary recovery as the parent compound. The urinary recoveries after oral administration ofprodrugs to mice are shown in Table 4 . Improved urinary recovery was observed in all of the derivatives (ll~14). Among them, especially, the pivaloyloxymethyl a Compounds(50 mg/kg) were orally administered to mice (n = 5) and urinary recovery was determined by the same method described in Table 1 . b GV-1 18819 was synthesized according to Glaxo's patent procedure.
ester ll and the 1-methylcyclohexylcarbonyloxymethyl ester 12 had excellent urinary recoveries of 47% and 55%, respectively. Pivaloyloxymethyl ester 15 prepared from the (S)-isomer 6n showed lower urinary recovery than ester ll of the (i?)-isomer 6m. These results reflect the better biological stability of the (7Q-isomer. The pivaloyloxymethyl ester 16 of the 1 -H carbapenem 7m was hardly recovered in urine probably due to the chemical and biological instability of 7m and 16.
In order to find the best ester promoiety, the pharmacokinetics of prodrugs ll and 12 were compared with each other in dogs. Results are listed in Table 5 .
The pivaloyloxymethyl ester ll showed better profiles than the 1 -methylcyclohexylcarbonyloxymethyl ester 12.
The maximum plasma level (Cmax) for ll was 6.1 jug/ml and the plasma half life (T1/2) was 0.90 hours at an oral dose of lOmg/kg as the parent carbapenem 6m. The absolute oral bioavailability of ll was approximately twice that of 12.
Based on good oral absorption and potent antibacterial activity, the prodrug ll showed excellent therapeutic efficacy against systemic infections in mice. It was highly effective especially against infections caused by resistant strains of bacteria, to which oral cephalosporins had been inactive.22)
Through these experiments the pivaloyloxymethyl ester ll was selected as the most promising compound for further evaluation. Preparation of (i?)-4-Mercapto-2-oxopyrrolidine (3m) i) (tS)-4-Methanesulfonyloxy-2-oxopyrrolidine 9
To a solution of (S)-4-hydroxy-2-oxopyrrolidine 8 (1.90 g, 18.8 mmol) in pyridine (100 ml), methanesulfonyl chloride (2.26 g, 19.7mmol) was added dropwise under ice-cooling. The mixture was stirred at room temperature for 1.5 hours, after which the reaction mixture was concentrated by evaporation under reduced pressure. Aqueous NaHCO3 was then added to the mixture, and the mixture was again concentrated to dryness by evaporation under reduced pressure. A mixture of EtOAcMeOH (1 : 1) was then added to the resulting residue.
The insoluble portion was removed by filtration and the soluble portion was concentrated by evaporation under reduced pressure. The residue obtained from the soluble portion was chromatographed through silica gel (Merck 9385, 150ml) with EtOAc-MeOH (from 9: 1 to 4: 1) as the eluent to give a crystalline residue. iii) (7?)-4-Mercapto-2-oxopyrrolidine 3m
To a solution of the compound (R)-10 (375mg, 2.35 mmol) in MeOH(5ml) was added 1 n NaOMe in MeOH (2.35 ml, 2.35 mmol) under ice-cooling, and the mixture was stirred for 20minutes. To the mixture was added 1 n aq. HC1 (2.35 ml, 2.35 mmol), and then the mixture was concentrated to dryness by evaporation under reduced pressure. EtOAc was added to the residue and insoluble matter was removed by filtration. 
To a solution of the compound 4m (390 mg, 0.78 mmol) in a mixture of THF(19ml) and 0.1m aq. phosphate buffer (pH 7.0) (18ml) was added 10% Pd-charcoal (300 mg), and the mixture was stirred vigorously at 30°C in an atmosphere of hydrogen for 2.5 hours. The catalyst was removed by filtration from the reaction mixture, and the nitrate was washedtwice with Et2O. Theaqueous layer wasthen concentrated by evaporation under reduced pressure, and the resulting residue was chromatographed through MCI GEL CHP-20P (Mitsubishi Kasei Corporation, 75~150/mi, 50ml) developed with water. The desired fraction was concentrated to 10ml, and then lyophilized to give the title compound6m as a colorless powder (225mg, 0.65mmol, 83% yield); 
To a solution of 4-nitrobenzyl (li?,5*S,65')-2-diphenyrphosphoryloxy-6-[(7?)- 
To a solution of the compound 4n (648 mg, 1.40 mmol) in a mixture of THF(33ml) and 0.1m aq. phosphate buffer (pH 7.0) (33ml) was added 10% Pd-charcoal (700 mg), and the mixture was stirred vigorously at 22°C in an atmosphere of hydrogen for 1.5 hours. The catalyst was removed by filtration from the reaction mixture, and the filtrate was washed twice with Et2O. The aqueous layer was then concentrated by evaporation under reduced pressure, and the resulting residue was chromatographed through Cosmosil 75C18 PREP (60ml) developed with water. The desired fraction was concentrated to 10ml, and then lyophilized to give the title compound 6n as a colorless powder (246mg, 0.70mmol, 50% yield); 
To a solution of 4-nitrobenzyl 
To a solution of the compound 5m (1000mg, 2.23mmol) and NaHCO3 (187mg, 2.23mmol) in the mixture of THF (30ml) and H2O (25ml) was added 10% Pd-charcoal (1000 mg), and the mixture was stirred vigorously at 30°C in an atmosphere of hydrogen for 1.5 hours. The catalyst was removed from the reaction mixture by nitration, and the nitrate was washed twice with EtOAc. The aqueous layer was then concentrated by evaporation under reduced pressure, and the resulting residue was chromatographed through Cosmosil 75C18 PREP (20g) developed with water. The desired fraction was concentrated to 10 ml, and then lyophilized to give the title compound 7mas a colorless powder (622mg, 1.86mmol, 83% yield); 3.16 (1H, dd, J= 17.4 and 8.6Hz), 3.24 (1H, dd, /=17.4 and 9.6Hz), m), 3.89 (1H, dd, .7=11.3 and 7.6Hz), 4.09 (1H, m), m The relative hydrolysis rate was determined by using 20% homogenate of kidney cortex from mice. An equi-volume of homogenate was added to 50 mMMOPS buffer (pH 7.0) which containing compounds of tested (2mM, final concentration: 1 mM)and the mixture was incubated at 37°C. At appropriate time intervals, portion of mixture was transferred to another test tube that contained 3-times volumeof methanol to stop enzymatic reaction. After vortex and centrifugation, the supernatants were injected to HPLC. The HPLCconditions are as follows: Column; A-312 ODS(6mmi.d. x 150mm length) from YMC, eluent; 20mM MES buffer (pH 6.0)-methanol (8 : 2), flow rate; 1.0ml/minute and UV detection at 300 nm. The hydrolysis rates of compounds were determined from plots of peak areas of the compoundsagainst time of samplings and expressed as relative hydrolysis rate against compound 6m. DHP-I activity of the homogenate was confirmed by the method of Campbell23) using glycyldehydrophenylalanine as a substrate.
Urinary Recovery of Carbapenems in Mice i ) Admi ni st r at i on Carbapenems 6a~n and 7m (dose: 50 mg/kg as sodium salt) were dissolved in water and then subcutaneously administered to mice (n=5, SPF ddY strain). A mixture ofcilastatin sodium and carbapenems 6m, 6n and 7m MAY 1997 (dose: 50mg/kg each as sodium salt) was dissolved in water and then subcutaneously administered to mice (n= 5, SPF ddY strain). Carbapenem esters ll~16 (dose: 50mg/kg as 6m, 6n and 7m) suspended in 0.5% tragacanth were orally administered to mice (n = 5, SPF ddY strain).
ii) Determination of Urinary Recovery
Urine was collected at 8 hours and 24 hours after administration. Excretion as the parent carbapenemwas determined by bioassay using Bacillus subtilis ATCC 6633. Urinary recovery (%, 0~24 hours) was calculated based on the excretion and the initial dose.
Pharmacokinetic Parameters of Carbapenems in Dogs i) Administration
Carbapenem 6m (dose: lOmg/kg) dissolved in water was intravenously administered to dogs (n= 3, Beagle). Carbapenem esters ll and 12 (dose: lOmg/kg as 6m) dissolved in dimethylacetamide -polyethyleneglycol 400 -water (1 :4: 5) were orally administered to dogs (n=3, Beagle).
ii) Determination of Pharmacokinetic Parameters
The concentration of R-95867 in blood was measured by HPLCmethod at suitable intervals after administration. Pharmacokinetic parameters were determined by the simulation program.
